Suppr超能文献

消癌解毒方抗弥漫大 B 细胞淋巴瘤的作用机制:体内外研究。

Determination and mechanism of Xiao-Ai Jie-Du decoction against diffuse large B-cell lymphoma: In silico and In vitro studies.

机构信息

Department of Hematology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China; The First Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210023, China.

National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing, 210023, China.

出版信息

J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117271. doi: 10.1016/j.jep.2023.117271. Epub 2023 Oct 12.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Xiao-Ai Jie-Du decoction (XAJDD) has been used in clinical practice to treat diffuse large B-cell lymphoma (DLBCL); its prescriptions vary based on the pathogenesis of patients.

AIM OF THE STUDY

We aimed to determine the core formula of XAJDD and investigate its mechanism of action against DLBCL.

MATERIALS AND METHODS

Apriori data mining of 187 clinical cases (including 421 Traditional Chinese Medicines, TCMs) was conducted to retrieve the core formula of XAJDD. Comprehensive in silico modeling was used to identify potential active components and corresponding targets. The potential targets of 16 compounds were identified based on network pharmacology using in silico modeling. Thereafter, experimental determination of the active compounds and their mechanism of action in treating DLBCL was performed using different assays (including CCK-8, Annexin V-FITC/PI double-staining, Western blot, and flow cytometry assays).

RESULTS

The core formula of XAJDD included six herbs: Astragalus mongholicus Bunge (Huangqi, family: Fabaceae), Scutellaria barbata D. Don (Banzhilian, family: Lamiaceae), Prunella vulgaris L. (Xiakucao, family: Lamiaceae), Smilax glabra Roxb. (Tufuling, family Smilacaceae) and Fritillaria thunbergii Miq. (Dabei, family: Liliaceae), and Curcuma zanthorrhiza Roxb. (Ezhu, family: Zingiberaceae); Databases including 62 druggable compounds and 38 DLBCL-related structural targets were constructed; ∼0.3 million data points produced by computational modeling based on potential compounds and targets six components from XAJDD, including astibin, folic acid, baicalin, kaempferol, quercetin, and luteolin, significantly inhibited DLBCL cell proliferation, induced apoptosis, and suppressed the expression of key oncogenes.

CONCLUSION

This study provides an integrated strategy for determining the core formula of XAJDD and reveals the molecular mechanisms underlying the treatment of DLBCL, which were consistent with the principle of "monarch (Jun), minister (Chen), adjunctive (Zuo), and guide (Shi)", confirming that XAJDD may serve as a promising natural therapeutic agent against DLBCL.

摘要

民族药理学相关性

消癌解毒汤(XAJDD)已在临床实践中用于治疗弥漫性大 B 细胞淋巴瘤(DLBCL);其处方因患者的发病机制而异。

研究目的

我们旨在确定 XAJDD 的核心配方,并研究其治疗 DLBCL 的作用机制。

材料和方法

对 187 例临床病例(包括 421 种中药)进行了先验数据挖掘,以检索 XAJDD 的核心配方。综合计算机模拟用于识别潜在的活性成分和相应的靶点。基于网络药理学,使用计算机模拟确定了 16 种化合物的潜在靶点。然后,使用不同的测定方法(包括 CCK-8、Annexin V-FITC/PI 双重染色、Western blot 和流式细胞术),实验测定了活性化合物及其治疗 DLBCL 的作用机制。

结果

XAJDD 的核心配方包括六种草药:蒙古黄芪(黄芪,豆科)、黄芩(黄芩,唇形科)、夏枯草(夏枯草,唇形科)、菝葜(土茯苓,菝葜科)和浙贝母(浙贝母,百合科)和姜黄(莪术,姜科);构建了包含 62 种可成药化合物和 38 个 DLBCL 相关结构靶点的数据库;基于 XAJDD 中六种成分的潜在化合物和靶点,计算建模产生了约 0.3 百万个数据点,包括 astibin、叶酸、黄芩苷、山奈酚、槲皮素和木樨草素,显著抑制了 DLBCL 细胞的增殖,诱导了细胞凋亡,并抑制了关键癌基因的表达。

结论

本研究提供了一种确定 XAJDD 核心配方的综合策略,并揭示了治疗 DLBCL 的分子机制,这与“君、臣、佐、使”的原则一致,证实 XAJDD 可能是一种有前途的天然治疗 DLBCL 的药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验